GenSci128
/ GeneScience
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2025
A Phase I, Multicenter, Multinational, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation
(ChiCTR)
- P1 | N=82 | Not yet recruiting | Sponsor: Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
New P1 trial • Solid Tumor • KRAS • TP53
1 to 1
Of
1
Go to page
1